Combined effects of brachial pulse pressure and sialic acid for risk of cardiovascular events during 40 years of follow-up in 37 843 individuals

Khalili, Payam; Sundström, Johannes; Franklin, Stanley S.; Jendle, Johan; Lundin, Fredrik; Jungner, Ingmar; Nilsson, Peter M.

doi:10.1097/hjh.0b013e32835606ae

Cited by 13 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sialic acid was shown to be positively associated with TNFα and IL-6 [65] and multiple studies have shown positive associations of total serum sialic acid with CVD, stroke and mortality [65][66][67][68]. A recent study reported that sialic acid was an independent risk marker for CVD during 40 years follow-up among Swedish individuals [69]. Taken together, sialic acid is a marker of systemic inflammation that can be used for risk assessment in subjects with CVD, heart failure and T2DM [65][66][67]69,70].…”

Section: Glycoprotein Assays and Cardiometabolic Disordersmentioning

confidence: 98%

See 1 more Smart Citation

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Connelly

Gruppen

Otvos

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

The physiological function initially attributed to the oligosaccharide moieties or glycans on inflammatory glycoproteins was to improve protein stability. However, it is now clear that glycans play a prominent role in glycoprotein structure and function and in some cases contribute to disease states. In fact, glycan processing contributes to pathogenicity not only in autoimmune disorders but also in atherosclerotic cardiovascular disease, diabetes and malignancy. While most clinical laboratory tests measure circulating levels of inflammatory proteins, newly developed diagnostic and prognostic tests are harvesting the information that can be gleaned by measuring the amount or structure of the attached glycans, which may be unique to individuals as well as various diseases. As such, these newer glycan-based tests may provide future means for more personalized approaches to patient stratification and improved patient care. Here we will discuss recent progress in high-throughput laboratory methods for glycomics (i.e. the study of glycan structures) and glycoprotein quantification by methods such as mass spectrometry and nuclear magnetic resonance spectroscopy. We will also review the clinical utility of glycoprotein and glycan measurements in the prediction of common low-grade inflammatory disorders including cardiovascular disease, diabetes and cancer, as well as for monitoring autoimmune disease activity.

show abstract

Section: Glycoprotein Assays and Cardiometabolic Disordersmentioning

confidence: 98%

“…A recent study reported that sialic acid was an independent risk marker for CVD during 40 years follow-up among Swedish individuals [69]. Taken together, sialic acid is a marker of systemic inflammation that can be used for risk assessment in subjects with CVD, heart failure and T2DM [65][66][67]69,70].…”

Section: Glycoprotein Assays and Cardiometabolic Disordersmentioning

confidence: 99%

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Connelly

Gruppen

Otvos

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

show abstract

“…Sialic acid has been well described in studies of cardiovascular disease as a marker of systemic inflammation and is a predictor of mortality. 36,37 Abnormal sialyation due to a genetic defect is reported as the cause of DCM in a mouse model, possibly via altered Ca 2+ handling. 38 Our results also support an association between sialyation and advanced DCM.…”

Section: Changes In Metabolites Reflect Pathophysiologic Pathways Drmentioning

confidence: 99%

Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy

Verdonschot

Wang

Bilsen

et al. 2020

Journal of Cardiac Failure

View full text Add to dashboard Cite

Background: Metabolomic profiling may have diagnostic and prognostic value in heart failure. This study investigated whether targeted blood and urine metabolomics reflects disease severity in patients with nonischemic dilated cardiomyopathy (DCM) and compared its incremental value on top of N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Methods and Results: A total of 149 metabolites were measured in plasma and urine samples of 273 patients with DCM and with varying stages of disease (patients with DCM and normal left ventricular reverse remodeling, n = 70; asymptomatic DCM, n = 72; and symptomatic DCM, n = 131). Acylcarnitines, sialic acid and glutamic acid are the most distinctive metabolites associated with disease severity, as repeatedly revealed by unibiomarker linear regression, sparse partial least squares discriminant analysis, random forest, and conditional random forest analyses. However, the absolute difference in the metabolic profile among groups was marginal. A decision-tree model based on the top metabolites did not surpass NT-proBNP in classifying stages. However, a combination of NT-proBNP and the top metabolites improved the decision tree to distinguish patients with DCM and left ventricular reverse remodeling from symptomatic DCM (area under the curve 0.813 § 0.138 vs 0.739 § 0.114; P = 0.02). Conclusion: Functional cardiac recovery is reflected in metabolomics. These alterations reveal potential alternative treatment targets in advanced symptomatic DCM. The metabolic profile can complement NT-proBNP in determining disease severity in nonischemic DCM.

show abstract

“…Over the past few years, clinical data confirmed the association between circulating SA levels and MS [10,11]. Serum SA levels are often elevated in subjects with MS and serum SA is also a potential risk factor for cardiovascular disease [12]. …”

Section: Introductionmentioning

confidence: 99%

Association between Serum Sialic Acid Levels and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

Mao²,

Zhang³

et al. 2015

Ann Nutr Metab

View full text Add to dashboard Cite

Background: To assess the association between serum sialic acid (SA) levels and nonalcoholic fatty liver disease (NAFLD) in a Chinese population. Methods: A cross-sectional study was performed among 3,898 Chinese who took their annual health examination. Serum SA levels and other clinical and laboratory parameters were measured. Results: A total of 18.11% fulfilled the diagnostic criteria of NAFLD. NAFLD subjects with/without metabolic syndrome (MS) had significantly higher serum SA levels than those without NAFLD. Serum SA levels were significantly and positively correlated with components of MS (body mass index, systolic blood pressure, diastolic blood pressure, triglyceride and fasting plasma glucose) in the NAFLD group. Stepwise logistic regression analysis showed that SA levels were significantly associated with the risk factor for NAFLD. Serum SA levels were negatively correlated with the FIB-4 score, and lower serum SA levels were independent factors predicting advanced fibrosis in subjects with NAFLD. Conclusions: Our results showed a significant association between serum SA levels and NAFLD.

show abstract

Combined effects of brachial pulse pressure and sialic acid for risk of cardiovascular events during 40 years of follow-up in 37 843 individuals

Abstract: Sialic acid but not PP was an independent risk factor for CVD. The risk induced by PP is highly affected by MAP. This suggests that both estimated arterial stiffness and inflammation contribute through different pathways to risk of CVD.

Cited by 13 publications

References 35 publications

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer

Metabolic Profiling Associates with Disease Severity in Nonischemic Dilated Cardiomyopathy

Association between Serum Sialic Acid Levels and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

Contact Info

Product

Resources

About